Showing results (291-300 of 411) with videos related to

Sort By:
Pageof 42
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 13, 2018
Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ<sub>1-42</sub>, total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40Harald Hampel, Nicola Toschi, Filippo Baldacci, et al.
Journal of Alzheimer'S Disease : JAD|July 22, 2017
Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional StudySimone Lista, Nicola Toschi, Filippo Baldacci, et al.
Neurodegenerative Disease Management|March 30, 2023
The amyloid-β pathway in Alzheimer's disease: a plain language summaryHarald Hampel, Yan Hu, John Hardy, et al.
Neurodegenerative Disease Management|July 22, 2022
The use of lumbar puncture and safety recommendations in Alzheimer's disease: a plain language summaryHarald Hampel, Aya Elhage, Leslie M Shaw, et al.
Clinical Chemistry and Laboratory Medicine|December 14, 2006
Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodiesHugo Vanderstichele, Karen De Vreese, Kaj Blennow, et al.
Archives of General Psychiatry|January 7, 2004
Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid studyHarald Hampel, Katharina Buerger, Raymond Zinkowski, et al.
Med (New York, N.Y.)|May 10, 2025
The impact of real-world evidence in implementing and optimizing Alzheimer's disease careHarald Hampel, Gang Li, Michelle M Mielke, et al.
Pageof 42